Literature DB >> 2985101

Ethnic differences in human lymphocytic cyclic AMP production after isoprenaline stimulation and propranolol blockade.

C P Venter, S Daya, P H Joubert, W J Strydom.   

Abstract

The stimulatory effects of isoprenaline on human lymphocytic cyclic AMP (cAMP) and blockade by propranolol were studied in vitro in healthy Black and White volunteers. Basal levels of lymphocytic cAMP were significantly higher in Blacks than in Whites. Stimulation with isoprenaline caused a dose-related increase in cAMP, which was in concentrations of 10(-9) to 10(-5)M significantly greater in Blacks than in Whites. Blockade by 10(-4)M propranolol did not affect basal cAMP levels significantly, but increases in cAMP levels were significantly smaller in both groups after 10(-9) to 10(-2)M isoprenaline, while differences between cAMP levels in Blacks and Whites were still significant at concentrations 10(-9) to 10(-3)M. The increased cAMP concentration in lymphocytes of Blacks probably reflects a higher degree of beta 2-adrenoceptor activity which could be due to either a greater number and/or greater sensitivity of lymphocytic beta 2-adrenoceptors in Blacks than in Whites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985101      PMCID: PMC1463703          DOI: 10.1111/j.1365-2125.1985.tb02630.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Effect of disopyramide on left ventricular performance: the relationship of free and total concentrations of the drug and of its mono-N-dealkylated metabolite to noninvasive indices of function.

Authors:  G W Holt; R L Norris; P J Ravenscroft; J H Bett; L G Dryburgh; C M Boyle
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

2.  An inter-racial study of the prevalence of hypertension in an urban South African population.

Authors:  Y K Seedat; M A Seedat
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

3.  The beta-adrenoceptor of the human lymphocyte and human lung parenchyma.

Authors:  M E Conolly; J K Greenacre
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

4.  The selective action of beta-adrenoceptor blocking drugs and the nature of beta1 and beta2 adrenoceptors.

Authors:  A J Coleman; A R Somerville
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

5.  Comparison of four different beta-adrenoceptor blocking drugs on lymphocyte isoprenaline-stimulated cyclic AMP production.

Authors:  D R Lima; S Kilfeather; A Hedges; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

6.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

7.  Once-daily atenolol in hypertensive Zimbabwean blacks. A double-blind trial using two different doses.

Authors:  C P Abson; L M Levy; G Eyherabide
Journal:  S Afr Med J       Date:  1981-07-11

8.  Ethnic differences in beta-1-adrenoceptor sensitivity.

Authors:  C P Venter; P H Joubert
Journal:  S Afr Med J       Date:  1982-11-27

9.  Ethnic differences in response to beta 1-adrenoceptor blockade by propranolol.

Authors:  C P Venter; P H Joubert
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

  9 in total
  3 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  G-protein-coupled receptor kinase activity is increased in hypertension.

Authors:  R Gros; J L Benovic; C M Tan; R D Feldman
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 3.  Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.

Authors:  Lizzy M Brewster; Yackoob K Seedat
Journal:  BMC Med       Date:  2013-05-30       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.